DiaCarta, Inc., a Hayward, CA-based biotechnology company, raised $8m in Series A financing.
Shanghai-based BioVeda China Fund made the investment.
The company intends to use the funds to expand its product portfolio and support global commercialization. In conjunction with the funding, Dr. Weixin Xu of BVCF will join DiaCarta’s board of directors.
Led by Aiguo Zhang, Ph.D., President & CEO, DiaCarta is a Translational Genomics and Molecular Diagnostics company. The company has CE/IVD assays for highly sensitive mutation detection in EGFR, KRAS, NRAS, BRAF, PIK3CA and JAK-2. QClamp™mutation detection assays utilize a novel xeno-nucleic acid (XNA) clamping technology to suppress amplification of wild-type DNA allowing selective amplification of mutant DNAs in real-time PCR. The QuantiVirus® HPV E6/E7 mRNA tests detect HPV E6/E7 mRNA in cervical and oral cancer. Assays are based on branched DNA signal amplification technology, performed without RNA purification or RT-PCR and do not require a clean room environment. Assays are CFDA (Chinese FDA) and CE/IVD cleared.